

For the use of Registered Medical Practitioner or Hospital use or Laboratory use only

## **Xylocard™ Injection**

### **Composition**

Each ml of solution contains:

Lignocaine Hydrochloride I.P. 21.3 mg corresponding to 20 mg of anhydrous substance.

No preservative is added.

**Description :** Lignocaine (Xylocard™ ) reduces the excitability of the myocardium and thus opposes the formation of ectopic foci. Xylocard™ thus suppresses ventricular extrasystoles and ventricular tachyarrhythmias. Xylocard™ is intended for the prophylaxis of these arrhythmias and for the suppression of arrhythmias. Xylocard™ is practically lacking in hypotensive and vasodilator properties. The function of the sinus node is not influenced and neither is atrio-ventricular conduction. Xylocard™ differs in this respect from certain other antiarrhythmic agents. Treatment with Xylocard™ is flexible owing to the rapid distribution, metabolism and excretion. During the first half hour after and intravenous injection the blood level of lignocaine declines with a half-life of 10-15 minutes owing to the rapid distribution to various tissues including the heart. After this initial phase, the half life is 90-120 minutes. During continuous infusion steady state is reached after 6-8 hours. In order to achieve an adequate blood concentration as rapidly as possible and to maintain the concentration at a constant level, one or more intravenous injections must be given initially. Breakdown occurs mainly in the liver and the metabolites are excreted via the kidneys.

### **Indications:**

- **Cardiac arrhythmias:** Prophylaxis and treatment of ventricular extrasystoles and ventricular tachyarrhythmias, especially in connection with myocardial infarction, mechanical irritation of the myocardium during cardiac surgery or diagnostic procedures (e.g. cardiac catheterization and angiocardiology), digitalis intoxication and intoxication with tricyclic antidepressants.
- Status epilepticus.

**Adverse Effects:** Drowsiness, persistent dizziness, paraesthesia, tinnitus, disorientation, blurred vision, tremor, convulsions, loss of consciousness, hypotension, bradycardia and respiratory depression.

**Dosage: Cardiac arrhythmias:** In the treatment of ventricular arrhythmias an intravenous injection is given first, followed by an intravenous drip. **A. Bolus injection with Xylocard™ 100 mg/5 ml (2%)** Normal dose: 2.5-5ml (50-100mg of lignocaine hydrochloride). This normal dose corresponds to 1mg/kg body weight per injection. The intravenous injection should be given at a rate of 25-50 mg/minute. **B. Intravenous drip with Xylocard™ 1000 mg/50 ml (2%) diluted.** Xylocard™ 1000 mg/50ml (2%) is diluted to 500 ml in an infusion solution. Normally, 2-4 mg/minute is given by continuous intravenous drip (adults). In certain cases doses higher than 4 mg/minute may be needed to achieve antiarrhythmic effect.

**Presentation :** Xylocard™ 2%, 30 ml vial

For further information please contact:

AstraZeneca Pharma India Ltd.  
Bellary Road, Hebbal  
Bangalore – 560 024